On June 27, 2025, Cantor Fitzgerald analyst Timur Ivannikov reiterated an "Overweight" rating for ProQR Therapeutics (PRQR, Financial). The analyst maintained the price target at $8.00, unchanged from the prior target, indicating confidence in the stock's potential performance.
ProQR Therapeutics, with its ticker PRQR, continues to hold an "Overweight" rating, suggesting a positive outlook from the analytical perspective of Cantor Fitzgerald. The maintained price target of $8.00 reflects steady expectations for the company's market value.
The rating update comes amidst a stable market environment, with no change in the envisioned price target for ProQR Therapeutics (PRQR, Financial). This stability in the rating and price target reflects continuing faith in the company's business strategies and future growth prospects.
All financial figures are represented in USD. The ticker PRQR is listed on NASDAQ.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for ProQR Therapeutics NV (PRQR, Financial) is $9.17 with a high estimate of $14.27 and a low estimate of $4.08. The average target implies an upside of 324.64% from the current price of $2.16. More detailed estimate data can be found on the ProQR Therapeutics NV (PRQR) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, ProQR Therapeutics NV's (PRQR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ProQR Therapeutics NV (PRQR, Financial) in one year is $3.66, suggesting a upside of 69.44% from the current price of $2.16. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ProQR Therapeutics NV (PRQR) Summary page.
